Summary: Advancing global health equity requires a paradigm shift in precision oncology, which currently remains inaccessible to most patients worldwide because of the high cost and long turnaround time of sequencing-based biomarkers. Recent developments in artificial intelligence inference from routine histopathology slides and blood tests are now enabling rapid cost-effective prediction of survival of patients with cancer and treatment response in both developed and under-resourced regions globally.
Hoang et al. (Mon,) studied this question.